Searched for: in-biosketch:true
person:leporh01
The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia
Lepor, Herbert; Lepor, Norman E; Hill, Lawrence A; Trohman, Richard G
The QT interval is the electrocardiographic manifestation of ventricular depolarization and repolarization. Drug-induced long QT syndrome is characterized by acquired, corrected QT (QTc) interval prolongation that is associated with increased risk of torsade de pointes. Every physician must recognize if the drugs he or she prescribes prolongs the QTc interval, especially if the drug is prescribed for a chronic condition in older patients who are on polypharmacy. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia has allowed the development of drugs that are easier to administer and better tolerated. Because alpha-blockers generally have equivalent efficacy, this class of drugs is typically differentiated by safety and side effects. Studies suggest that alpha-blockers may vary in regard to their effect on the QT interval, and, therefore, on their predisposition to cause potentially life-threatening ventricular arrhythmias
PMCID:2483321
PMID: 18660858
ISSN: 1523-6161
CID: 95829
Penile Rehabilitation Postprostatectomy: Is There a Role for MUSE?
Lepor, Herbert; McCullough, Andrew
PMCID:2312350
PMID: 18470281
ISSN: 1523-6161
CID: 95830
Stromal AR inhibition of prostate cancer growth and invasion by stromal AR and association with androgen independent disease [Meeting Abstract]
Li, Y; Li, CX; Melamed, J; Walden, P; Peng, Y; Lepor, H; Garabedian, MJ; Lee, P
ISI:000254175300536
ISSN: 0022-5347
CID: 104578
Do candidates for focal therapy exist among a contemporary cohort of radical prostatectomy patients? [Meeting Abstract]
Tareen, Basir; Godoy, Guilherme; Sankin, Alex; Temkin, Steve; Lepor, Herbert; Taneja, Samir S
ISI:000254175300149
ISSN: 0022-5347
CID: 1872012
Men with unilateral prostate cancer have more favorable pathologic and oncologic outcomes than those with bilateral disease: Implications for focal therapy [Meeting Abstract]
Tareen, Basir; Sankin, Alex; Godoy, Guitherme; Temkin, Steve; Lepor, Herbert; Taneja, Samir S
ISI:000254175301472
ISSN: 0022-5347
CID: 1872022
Active surveillance of men with hgpin by empiric delayed interval biopsies demonstrates a significant long-term risk of cancer progression [Meeting Abstract]
Godoy, Guilherme; Huang, George; Tareen, Basir; Lepor, Herbert; Taneja, Samir S
ISI:000254175302698
ISSN: 0022-5347
CID: 1872042
The short-term and long-term effects of radical prostatectomy on lower urinary tract symptoms
Slova, Denisa; Lepor, Herbert
PURPOSE: We determined the long-term effect of radical prostatectomy on lower urinary tract symptoms. MATERIALS AND METHODS: Between October 1, 2000 and January 30, 2003, 587 men underwent open radical retropubic prostatectomy. Of these men 453 completed the American Urological Association symptom index at baseline, and 12 and 48 months. Mean changes in American Urological Association total, voiding and storage symptom scores were ascertained between baseline and 12 months (short term), baseline and 48 months (long term), and between 12 and 48 months (natural history of lower urinary tract symptoms without a prostate). Symptom scores were ascertained independently for men with baseline mild vs moderate/severe lower urinary tract symptoms. RESULTS: Clinically and statistically significant short-term and long-term improvements were observed in mean American Urological Association total, storage and voiding symptom scores for men presenting with moderate/severe lower urinary tract symptoms. The previously reported progression of lower urinary tract symptoms in the general population of men older than 40 years was not observed in our patients with an absent prostate. CONCLUSIONS: The current study provides compelling evidence that radical prostatectomy prevents the progression of lower urinary tract symptoms in men with and without baseline clinically significant lower urinary tract symptoms. This beneficial effect of radical prostatectomy on the natural history of lower urinary tract symptoms should be considered when weighing the risks and benefit of the treatment option for localized prostate cancer
PMID: 17936841
ISSN: 1527-3792
CID: 75457
Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome
Huang, Hong-Ying; Shariat, Shahrokh F; Sun, Tung-Tien; Lepor, Herbert; Shapiro, Ellen; Hsieh, Jer-Tsong; Ashfaq, Raheela; Lotan, Yair; Wu, Xue-Ru
As the terminal differentiation products of human urothelium, uroplakins (UPs) would be expected to diminish during urothelial tumorigenesis. Surprisingly, recent studies found UPs to be retained even by well-advanced urothelial carcinomas, suggesting that the loss of UPs does not strictly parallel urothelial transformation. Little is known, however, about whether the status of UPs is associated with a particular pathologic parameter, the tumor's biological behavior, or patient outcome. Here we assessed UP expression by immunohistochemistry on tissue arrays from 285 patients with bladder urothelial carcinomas or nontumor conditions. UPs were expressed in all 9 normal urothelial specimens, 63 of 74 (85%) patients with non-muscle-invasive urothelial carcinomas on transurethral resection, 104 of 202 (51.5%) patients who underwent radical cystectomy for advanced urothelial carcinomas, and 33 of 50 (66%) lymph node metastases. Normally associated with urothelial apical surface, UPs were localized aberrantly in tumors, including microluminal, basal-laminal, cytoplasmic, or uniform patterns. In non-muscle-invasive diseases, there was no association between UP expression and disease recurrence, progression, or mortality. In contrast, in invasive diseases, absent UP expression was significantly associated with advanced pathologic stage, lymph node metastases, disease recurrence, and bladder cancer-specific mortality (P = .042, P = .035, P = .023, and P = .022, respectively) in univariate analyses. Furthermore, UP status was independent of key cell-cycle regulators, including p53, pRb, p27, and cyclin D1, thus excluding a functional link between these 2 groups of proteins. Our data demonstrate for the first time that persistent UP expression is associated with a favorable clinical outcome and that UPs may be used as adjunct markers for predicting the prognoses of patients with invasive and metastatic bladder carcinomas. Our results also suggest that UP-positive and -negative carcinomas have different clonal origins or may be derived from different cancer stem cells
PMCID:2778836
PMID: 17707461
ISSN: 0046-8177
CID: 73404
Inguinal hernias in men undergoing open radical retropubic prostatectomy
Lepor, Herbert; Robbins, David
OBJECTIVES: To determine the incidence of inguinal hernias in men undergoing open radical retropubic prostatectomy (RRP). METHODS: The incidence of preoperative and postprostatectomy inguinal hernias were determined by a retrospective chart review and questionnaire survey of 1130 consecutive men who underwent open RRP by a single surgeon from October 2000 to October 2005. A preoperative inguinal hernia was diagnosed by the physical examination or abdominal computed tomography findings. The incidence of new postoperative hernias was ascertained by the patients' responses to a survey indicating the development of a new groin bulge or hernia. RESULTS: Of the 1130 patients, 146 (13%) had a preoperative inguinal hernia. Increasing age and lower body mass index were significantly associated with the detection of a preoperative inguinal hernia. The sensitivity of detecting an inguinal hernia by physical examination and routine abdominal computed tomography preoperatively was 96.3% and 42.5%, respectively. Also, 8% of men developed a new hernia. CONCLUSIONS: Although abdominal computed tomography can identify inguinal hernias in men undergoing open RRP, the test's sensitivity is inferior to that of a simple physical examination. All candidates for open RRP should undergo a careful physical examination to identify asymptomatic inguinal hernias. Our findings suggest that the previously reported high incidence of symptomatic inguinal hernias that developed after open RRP can be explained by a failure to diagnose preexisting inguinal hernias and the development of new hernias
PMID: 18068454
ISSN: 1527-9995
CID: 75488
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia
Johnson, Theodore M 2nd; Burrows, Pamela K; Kusek, John W; Nyberg, Leroy M; Tenover, J Lisa; Lepor, Herbert; Roehrborn, Claus G
PURPOSE: We evaluated the effectiveness of single or combination drug therapy on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. MATERIALS AND METHODS: A total of 3,047 men with lower urinary tract symptoms/benign prostatic hyperplasia enrolled in the Medical Therapy of Prostatic Symptoms trial were randomly assigned to receive doxazosin alone, finasteride alone, combination therapy or placebo. Treatment effectiveness was assessed according to intent to treat by mean reduction in self-reported nightly nocturia at 1 and 4 years. A subgroup analysis by age (younger than 70 vs 70 years old or older) was also performed. RESULTS: Of the men 2,583 reported 1 or more episodes of nocturia and finished 12 or more months of the trial. Mean nocturia was similar in all groups at baseline. Mean nocturia was reduced at 1 year by 0.35, 0.40, 0.54 and 0.58 in the placebo, finasteride, doxazosin and combination groups, respectively. Reductions with doxazosin and combination therapy were statistically greater than with placebo (p <0.05). At 4 years nocturia was also significantly reduced in patients treated with doxazosin and combination therapy (p <0.05 vs placebo). In men older than 70 years (495) all drugs significantly reduced nocturia at 1 year (finasteride 0.29, doxazosin 0.46 and combination 0.42) compared to placebo (0.11, p <0.05). CONCLUSIONS: Doxazosin and combination therapy reduced nocturia more than placebo, but the net benefit of active drug compared to placebo was often modest with a net difference of less than 0.20 fewer nightly nocturia episodes at 1 and 4 years. Findings in men 70 years old or older were similar, with an even smaller effect observed for finasteride
PMID: 17869295
ISSN: 0022-5347
CID: 95833